You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Indication 1

Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.

Dosage 1

Bexsero is available as a white opalescent liquid suspension for injection in a pre-filled syringe and comes as a 0.5 ml dose.

Bexsero offers several schedule options with flexible dosing intervals, making it simple to fit with routine vaccination visits. 1

Bexsero Overview

The use of this vaccine should be in line with official recommendations.

Coadministration:

Bexsero can be given concomitantly with any of the following vaccine antigens, either as monovalent or as combination vaccines 1:

— Meningococcal groups A, C, W, Y conjugate

— Diphtheria, tetanus, acellular pertussis, inactivated polio

Haemophilus influenzae type b

— Hepatitis B

— Heptavalent pneumococcal conjugate

— Measles, mumps, rubella

— Varicella

Storage and stability 1

  • Shelf life: 3 years
  • Store in a refrigerator (2°C–8°C)
  • Do not freeze
  • Store in the original package in order to protect from light
  • Upon storage, a fine off-white deposit may be observed in the prefilled syringe containing the suspension
  • Before use, the pre-filled syringe should be well shaken in order to form a homogeneous suspension. 

View Resources

References:

  1. Bexsero Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/bexsero-suspension-for-injection-in-pre-filled-syringe-31445/spc Last Accessed: April 2021
  2. HSE Immunisation Guidelines. Available at: https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter13.pdf, Last Accessed: April 2021

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Bexsero is a registered trademark of the GlaxoSmithKline Group of Companies